Evidence map›Paper›PMID 40951531›Full record

ArticleJournal of clinical and translational hepatology2025

Cumulative Hepatitis B Surface Antigen/Hepatitis B Virus DNA Ratio in Immune-tolerant Hepatitis B Patients: A 10-year Follow-up Study.

Dawu Zeng, Yanfang Huang, Sheng Lin, Naling Kang, Yanxue Lin, Jiaji Jiang, Yueyong Zhu, Qi Zheng, Jiming Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and translational hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dawu ZengDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Yanfang HuangDepartment of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Clinical Research Center for Liver and Intestinal Diseases of Fujian Province, Fuzhou, Fujian, China.
Sheng LinLaboratory Department, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Naling KangDepartment of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Clinical Research Center for Liver and Intestinal Diseases of Fujian Province, Fuzhou, Fujian, China.
Yanxue LinDepartment of Infectious Diseases, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Jiaji JiangDepartment of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Clinical Research Center for Liver and Intestinal Diseases of Fujian Province, Fuzhou, Fujian, China.
Yueyong ZhuDepartment of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Clinical Research Center for Liver and Intestinal Diseases of Fujian Province, Fuzhou, Fujian, China.
Qi ZhengDepartment of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Clinical Research Center for Liver and Intestinal Diseases of Fujian Province, Fuzhou, Fujian, China.ORCID https://orcid.org/0000-0001-8006-7069
Jiming ZhangDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-5820-950X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment. This study aimed to investigate changes in the cumulative hepatitis B surface antigen (HBsAg)/HBV DNA ratio in immune-tolerant patients during the transition to the immune-active phase, and to evaluate its potential in predicting the risk of disease progression. Methods: This longitudinal study included 127 untreated immune-tolerant patients, who were followed for up to 10 years. An independent cohort of 109 subjects was retrospectively enrolled for external validation. The relationship between the cumulative HBsAg/HBV DNA ratio and the duration of immune tolerance or transition to the immune-active phase was examined. The predictive value of the ratio was assessed and validated. Results: The relationship between the cumulative HBsAg/HBV DNA ratio and disease progression risk showed a non-linear pattern: below a ratio of 1.791, the risk of disease progression decreased rapidly as the ratio increased; above 1.791, the risk plateaued. The area under the curve for predicting disease progression was 0.67, 0.64, and 0.85 for cumulative HBsAg, HBV DNA, and the HBsAg/HBV DNA ratio, respectively. Multivariable Cox regression analysis revealed the cumulative HBsAg/HBV DNA ratio as an independent predictor of disease progression, with higher ratios associated with a lower risk. Prediction models incorporating this ratio were developed and externally validated, demonstrating strong performance and clinical utility. Conclusions: The cumulative HBsAg/HBV DNA ratio is an independent factor influencing the duration of immune tolerance and shows superior predictive performance. It may serve as a valuable marker for assessing the risk of disease progression in patients with chronic HBV infection.

Indexed as

Chronic hepatitis BCirrhosisHBeAgHBsAgHepatitis B e-antigenHepatitis B surface antigenHepatitis B virusHepatitis B virus DNAHepatocellular carcinomaImmune-active phaseImmune-tolerant phaseInflammationLiver fibrosisPredictive model

Identifiers

PMID40951531
PMCPMC12422875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.